• November 17, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced that the European Commission has granted marketing authorization for SimparicaTM (sarolaner) chewable tablets, a once-monthly medication for the treatment of fleas, ticks and sarcoptic mange in dogs beginning at eight weeks of age. The approval follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use in September 2015. “The approval of Simparica givesmore...
  • August 5, 2015
    Sydney, New South Wales, Australia - August 5, 2015 – Zoetis today announced that the Hendra virus vaccine,Equivac® HeV, has received registration from the Australian Pesticides and Veterinary Medicines Authority (APVMA).“We at Zoetis are pleased that after nearly three years of positive uptake, Equivac® HeV vaccine has successfully been registered,” said Lance Williams, General Manager for Zoetis in Australia and New Zealand.  “The APVMA undertakes one of the most detailedmore...
  • August 3, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic,* a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. It represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientificmore...
  • March 19, 2015
    LONDON, UK - March 19, 2015 - Leading animal health company Zoetis Inc. unveiled its Centre for Digital Innovation (CDI) at the House of Lords today. Opened in the heart of London’s Tech City, the new Centre will create sophisticated digital products that enable data-driven decision-making to enhance precision farming and improve animal wellbeing for livestock and pets.Hosted by Lord Trees, the event was introduced by Lord de Mauley and attended by industry representatives including themore...
  • February 10, 2015
    FLORHAM PARK, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) today announced that it has completed the purchase of the animal health assets of Abbott for a purchase price of $255 million, having fulfilled all closing requirements. The purchase expands Zoetis’ companion animal product portfolio to bring veterinarians solutions for anesthesia and treating pain and serious illnesses such as diabetes. It also brings novel cancer and pain compounds to the Zoetis pipelinemore...
  • January 13, 2015
    New York, NY – January 13, 2015 — Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients. The research was made available this week in the Journal of Community and Supportive Oncology.The study, conducted by researchers at Mount Sinai Beth Israel, found that patients receiving intensive multi-modal concomitant radiation therapy and chemotherapymore...
  • December 1, 2014
    FLORHAM PARK, N.J., December 1, 2014 – Zoetis is pleased to announce that the American Animal Hospital Association (AAHA) has selected the company’s Pet Wellness Report® (PWR) as AAHA’s exclusive Preferred Business Provider for Health Risk Assessments in veterinary medicine. AAHA accredited hospitals are traditionally on the forefront of advancing new approaches to medical care for companion animals. The endorsement lends credibility to this innovative communication tool, which furthermore...
  • April 8, 2014
    Zoetis joined a new initiative working to advance the standards of small animal veterinary care across Africa. The African Small Companion Animal Network (AFSCAN) aims to facilitate the creation of a sustainable network of companion animal veterinarians, associations and specialist groups in sub-Saharan Africa. This network will facilitate the formation of new Small Animal Veterinary Associations (SAVAs) across the continent. Read the full press release here.more...
  • February 26, 2014
    FLORHAM PARK, N.J. - February 26, 2014 - The Winn Feline Foundation, in a unique funding opportunity sponsored by Zoetis Inc., announced today a call for proposals to address the assessment of pain, osteoarthritis, joint health and kidney disease in cats. A total of $100,000 is available to fund proposals of sufficient scientific merit, relevance and potential to impact feline health. Consideration will be given to proposals investigating novel biomarkers for assessing acute or chronicmore...
  • January 29, 2014
    PARIS, FRANCE, January 29, 2014 – Zoetis Inc. announced today the launch of Apoquel® (oclacitinib maleate), a novel therapy indicated for the treatment of pruritus (itching) associated with canine allergic dermatitis and the clinical manifestations of atopic dermatitis. Veterinarians across Europe now have a first-in-class treatment choice that targets the itch of allergic skin conditions in dogs.Apoquel is the first Janus Kinase (JAK) inhibitor approved for veterinary use. It provides rapidmore...